COMP <GO>
SMMT vs JNJ // RSI-14 & 200D SMA MOMENTUM
Summit Therapeutics Inc. Common Stock (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: SMMT 3
— JNJ 10
▲ RSI-14 & 200D SMA MOMENTUM LEADER: JNJ
LAST: $16.03 (-1.05%) • MKT CAP: $12.96B
rsi-technicals
50.7
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
rsi-technicals
60.4
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SMMT VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SMMT | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 25.50% | -60.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.50% | 2.97% | -5.47 | JNJ | /fcf-yield <GO> |
| Operating Margin | -36.30% | 34.70% | -71.00 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -29.80% | 28.50% | -58.30 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 11.00% | 6.00% | +5.00 | SMMT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.59 | +20.41 | SMMT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 7.20% | -0.40 | SMMT | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 50.7 | 60.4 | -9.63 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | 1.08 | -0.11 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.0x | 23.0x | +11.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $12.96B | $662.49B | -$649.54B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SMMT REV | JNJ REV | SMMT GROSS % | JNJ GROSS % | SMMT FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $94.19B | — | 67.9% | -$323.6M | $19.70B |
| FY 2024 | $0 | $88.82B | — | 69.1% | -$142.2M | $19.84B |
| FY 2023 | $0 | $85.16B | — | 44.0% | -$76.8M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SMMT // BETA 0.97
JNJ // BETA 1.08